Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus reuteri NCIMB 30242

What does the research say about Lactobacillus reuteri NCIMB 30242?

2 health outcomes synthesised

Research on Lactobacillus reuteri NCIMB 30242 has focused on two health outcomes: reduced blood cholesterol and improved blood lipid profiles, primarily in hypercholesterolemic adults. The strongest evidence is for reduced blood cholesterol, based on three studies, including one randomized controlled trial (n=127) that reported a 9.14% reduction in total cholesterol relative to placebo. No consistent effective dose has been established across studies.

Strongest evidence: The probiotic Lactobacillus reuteri NCIMB 30242 has moderate evidence for reducing blood cholesterol. All three studies reported beneficial small to moderate effects, with the most direct evidence coming from a randomized controlled trial in 127 hypercholesterolemic adults showing a 9.14% reduction in total cholesterol (p<0.001). However, no specific dose range was reported across studies.

Mixed or weaker evidence: For improved blood lipid profile, the evidence is low strength. All three studies reported beneficial effects, but only one was a randomized controlled trial showing statistically significant reductions in LDL-C/HDL-C ratio and apoB-100/apoA-1 ratio. The small evidence base (3 studies) and lack of consistent dosing make conclusions preliminary.

Effective dose patterns: No consistent effective dose was identified across outcomes. Specific doses were often not reported or were unclear in the available studies.

Population insights: The research consistently focuses on hypercholesterolemic adults. No other populations have been studied for this specific strain.

Notable caveats: The evidence base for both outcomes is small (only 3 studies each), so conclusions should be considered preliminary. Publication bias is a concern, as null-result studies may be underrepresented. For blood cholesterol, meta-analyses included multiple L. reuteri strains, and the beneficial effect for NCIMB 30242 is derived from subgroup analyses. For blood lipid profile, only one of three studies reported statistically significant findings.

Frequently asked

  • What is Lactobacillus reuteri NCIMB 30242 good for according to research?
    Research has studied this strain for two outcomes: reducing blood cholesterol and improving blood lipid profiles. The strongest evidence is for reducing blood cholesterol, with all three studies reporting small beneficial effects.
  • What dose of Lactobacillus reuteri NCIMB 30242 is typically used in studies?
    No consistent effective dose has been reported across studies. Some studies did not clearly specify the dose used, making it difficult to determine a standard range.
  • Who benefits most from Lactobacillus reuteri NCIMB 30242?
    The research has focused on hypercholesterolemic adults. All available studies were conducted in this population, so there is no evidence on effects in other groups.
  • Does Lactobacillus reuteri NCIMB 30242 help reduce blood cholesterol?
    Moderate evidence from three studies suggests it has a small beneficial effect on reducing blood cholesterol. The most direct randomized controlled trial (n=127) reported a 9.14% total cholesterol reduction. However, the evidence base is small and conclusions are preliminary.
  • Does Lactobacillus reuteri NCIMB 30242 improve blood lipid profiles?
    Low evidence from three studies suggests beneficial effects on blood lipid profiles, but only one randomized controlled trial showed statistically significant improvements in LDL-C/HDL-C ratio and other markers. The evidence is too small to draw firm conclusions.
  • Are there caveats or limitations in the research on Lactobacillus reuteri NCIMB 30242?
    Yes. The evidence base for both outcomes is small (only 3 studies each), and conclusions should be considered preliminary. Publication bias is possible, and for blood cholesterol, the strain-specific effects come from subgroup analyses. For blood lipid profile, only one study was statistically significant.

Most-studied combinations with Lactobacillus reuteri NCIMB 30242

most supplement research is combination research
Also studied with:Lactobacillus fermentum CECT5716 (2)

  • FLORASSIST Probiotic Heart Health

    By Life Extension

    4.6 (406 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $24.00
    		In
    Vitacost
    $23.99
    		In
    Vitamin Shoppe
    $-
    		Out
Back to top